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ScienceDirectAutoimmune and allergic diseases are major causes of
morbidity. Antigen-based immunotherapy (AIT) is
immunologically the most satisfying means of specifically
targeting only those T cells driving disease, thereby inducing
antigen-specific immune tolerance, with the lowest adverse
risk profile. AIT is highly effective in rodent models of T cell-
driven inflammation and is now in clinical trials. The range of
approaches to applying AIT in the clinic prevents a consensus
on the molecular basis for this form of tolerance. In particular,
there has been a paucity of information on how pre-activated
effector and memory T cells respond to AIT. New, advanced
murine models of AIT are beginning to deliver such information
at the cellular, biochemical, transcriptional and epigenetic
levels.
Addresses
1University of Glasgow, Institute of Infection, Immunity and
Inflammation, Sir Graeme Davies Building, 120 University Place,
Glasgow G12 8TA, UK
2University of Edinburgh, MRC Centre for Inflammation Research,
Queen’s Medical Research Institute, 47 Little France Crescent,
Edinburgh EH16 4TJ, UK
Corresponding author: MacLeod, Megan KL
(Megan.Macleod@glasgow.ac.uk)
Current Opinion in Pharmacology 2015, 23:11–16
This review comes from a themed issue on Immunomodulation
Edited by Stephen M Anderton and Simon Fillatreau
For a complete overview see the Issue and the Editorial
Available online 22nd May 2015
http://dx.doi.org/10.1016/j.coph.2015.05.003
1471-4892/# 2015 The Authors. Published by Elsevier Ltd. This is an
open access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).
Introduction
Autoimmune diseases and allergic conditions are caused
by inappropriate immune responses that attack either
self-tissues or innocuous environmental antigens, respec-
tively. Most current treatments for these conditions target
the symptoms of the diseases rather than offering cures.
Many of these treatments, especially in the context of
autoimmunity, lead to significant immunodeficiency that
can expose the patient to severe, sometimes life-threat-
ening, infections. Such disease-modifying drugs are usu-
ally given over a long period of time, often for the lifetime
of the individual. By contrast, specifically removing or
modifying only those immune cells that drive the allergicwww.sciencedirect.com or autoreactive immune response could lead to a perma-
nent cessation of the disease — a cure.
The CD4+ T cells believed to initiate and drive many
autoimmune and allergic conditions are activated through
their cell surface T cell receptor (TCR) that specifically
recognises the self-antigen or allergen. By targeting the
TCR, AIT aims to silence the damaging T cells whilst
leaving the rest of the immune system intact. Success in
animal studies and historical allergy treatments in humans
has led to clinical studies in both fields. Here we will
consider recent examples of AIT in both animal and
human studies and discuss the underlying immunological
mechanisms.
Immune tolerance — a physiologic basis for
immunotherapy
T cells gain their heterodimeric TCR through random
gene re-arrangement during thymic development. This is
essential to generate a broad repertoire of T cells that can
respond to the variable array of pathogens the host will be
exposed to over a lifetime. TCR gene re-arrangement also
generates T cells with the potential to be activated by
self-peptides. Many of these potentially destructive T
cells are deleted during negative thymic selection [1].
This ‘central tolerance’ is not complete, however. In all
individuals, some self-reactive T cells mature and migrate
to the periphery where, if activated, they have the poten-
tial to cause autoimmunity. To prevent this, ‘peripheral
tolerance’ mechanisms regulate T cell activation to both
self and innocuous foreign antigens, such as the dietary
and environmental antigens that can cause allergy.
A key mechanism by which peripheral tolerance is main-
tained is the presentation of antigen in non-inflammatory
contexts. Full T cell activation requires two signals stem-
ming from cell surface receptors delivered when the T
cell interacts with an antigen presenting cell (APC).
Signal 1 is provided by TCR binding to short antigenic
peptides presented by MHC molecules. Signal 2 (costi-
mulation) is delivered by a number of different receptor–
ligand pairs, upregulated in inflammatory environments.
Delivery of signal 1 alone leads to T cell tolerance either
as a consequence of T cell death, modulation of the T
cell’s ability to respond to further activation (often called
anergy), or the T cell gains regulatory function, capable
of suppressing the activation of other immune cells
(Figure 1) [2–4]. AIT aims to mimic these natural tolero-
genic processes by delivery of the appropriate self- or
allergen-derived peptide in the absence of inflammatoryCurrent Opinion in Pharmacology 2015, 23:11–16
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T cell activation requires two signals. CD4+ T cells are tolerised if they encounter their antigen (signal 1) presented by an antigen presenting cell
(APC) that has not been activated. Inflammation and/or infection cause APCs to upregulate costimulatory molecules that deliver signal 2 to T cells.
T cells that receive both signals 1 and 2 become activated and differentiate into effector cells. In the context of infection, effector T cells co-
ordinate the clearance of invading pathogens. If the T cells recognise allergen or self-antigens, the host can develop allergy or autoimmune
disease respectively. If a T cell receives a tolerising TCR signal in advance of encountering its antigen presented by an activated APC, the T cell
will not become fully activated — it is tolerant.signals. This attractively simple concept belies a complex
process which requires extensive knowledge of the target
antigen; the location, phenotype and function of the
‘disease-causing’ T cells; and an ability to track these
T cells to evaluate the success of any treatment.
Allergy
For over 100 years [5], immunotherapy has been practiced
in allergic individuals. Initially involving crude allergen
extracts, antigens are now carefully prepared to reduce
adverse events. Allergen-derived peptides rather than
whole antigens are often used as peptide immunotherapy
(PIT), particularly as these can be selected not to cross
link allergen-specific IgE, a process that can lead to
enhanced rather than reduced allergic symptoms, includ-
ing anaphylactic shock [6]. Increasing the dose of the
allergen over a period of months to years is thought to
modulate the allergen specific immune response includ-
ing inducing a switch from an IgE dominated antibody
response to IgG [7] and/or production of the regulatory
cytokine interleukin (IL)-10 [8]. More recent advances in
the ability to track allergen-specific T cells in the blood of
patients undergoing immunotherapy suggest that AIT
causes the deletion, rather than the modulation, of the
disease causing T cells [9,10].Current Opinion in Pharmacology 2015, 23:11–16 The route of delivery of the immunotherapy is likely to
affect the dose of antigen that reaches the immune
system. In Europe, the sublingual route is approved for
allergy immunotherapy while the subcutaneous route is
approved in the USA [5]. While the efficacies of these
two routes have rarely been compared directly, a recent
meta-analysis indicates that tablets designed to treat
grass pollen allergy and subcutaneous delivery of pollen
antigens can each reduce symptoms of rhinoconjuncti-
vitis to a similar extent [11]. Delivery of antigen can
also be increased by either direct injection into lymph
nodes with the aid of ultrasound or by binding the
antigen to particular adjuvants such as aluminium hy-
droxide [7,12].
Autoimmune disease
In allergy, the inciting antigen is usually well-defined.
This is far from the case for many autoimmune diseases.
Considerable progress has been made in recent years in
the identification of potential antigens in many autoim-
mune conditions [13–20]. However, pinning down the
specificity of the T cells that cause these diseases is a
complex process, further confused by the accumulation of
different antigenic targets as the disease progresses, a
process known as epitope spreading [21].www.sciencedirect.com
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have taken place or are currently ongoing. Individuals
considered at risk of diabetes have been given insulin or
the pancreatic enzyme, glutamine decarboxylase, Gad-
65, in an attempt to remove or modify the immune cells
that cause pancreatic b-cell destruction (reviewed in
[22]). These studies have found no delay in, or modifica-
tion of, disease progression. Such trials, as Harrison et al.
suggest, are unlikely to provide meaningful data without
biomarkers to evaluate the impact of the therapy [22].
Similar approaches have been made to reduce disease
progression in individuals with multiple sclerosis. Myelin
peptides delivered alone, in the context of self-MHC
molecules, or chemically fixed to patient cells have had a
variety of effects from some reduction in relapses, no
effect, or, in some cases, serious hypersensitivity
(reviewed in [23]). Hypersensitivity responses were
found in studies aiming to modulate the T cell response
using peptides with a slightly altered sequence compared
to the self peptide. Such altered peptide ligands (APLs)
have different TCR-binding affinities and consequently
provide altered signals for T cell activation leading to
quantitative and/or qualitative changes in the T cell
response. These effects are often specific for individual
TCRs, which makes clinical translation from reductionist
animal models to outbred human populations with more
complex TCR repertoires inevitably unreliable.
Modulation of T cell responses has also been observed in
rheumatoid arthritis (RA) patients given a peptide from
dnaJ, a heat shock protein, which shares similarities with
the RA ‘shared epitope’ [24,25]. Oral delivery of this
peptide led to improved clinical responses and a shift
from inflammatory to regulatory cytokine production. By
contrast, intranasal delivery of a potential RA autoanti-
gen, human cartilage glycoprotein-39, failed to provide
any additional benefit compared to placebo [26]. More
recent phase 1 studies in RA patients, and also in diabetic
patients, have delivered the tolerising antigen using
patient derived APCs. Dendritic cells (DCs), a key pop-
ulation of APCs, are differentiated from the patient’s
blood cells in the presence of tolerogenic signals, incu-
bated with antigens before transfer back into the patient
[27,28]. Such approaches ensure that the antigen is tar-
geted to APCs that are likely to interact with the disease-
causing T cells and can ameliorate disease in animal
models by either reducing T cell effector responses
and/or increasing immune regulation [29,30]. Likewise,
antigen can be targeted to DCs by binding it to nano-
particles. Such approaches have been successfully used in
animal models of allergy and autoimmunity [31,32].
As in allergy trials, the ability to track the target T cell
population will be crucial to evaluate the success, and
investigate the mechanisms of, disease modification.
Recent studies using MHC class II tetramers containingwww.sciencedirect.com RA-associated peptides show that, while healthy con-
trols and RA patients have similar numbers of RA-rele-
vant T cells, the T cell populations from patients are
more likely to have a memory T cell phenotype [33].
Memory T cells are generated following immune
responses and may, as discussed below, present a more
complex challenge to immunotherapy.
Mechanisms of action
Many animal studies have investigated the mechanisms
of tolerance induction following AIT (Figure 2 and
reviewed in [34]). Recent full genome transcriptional
analysis of T cells exposed to a dose escalation of peptide
suggest that, as in some of the human trials discussed
above, AIT shifts T cells towards production of the
regulatory cytokine, IL-10 [35]. In other experimental
scenarios, a single high dose of AIT can drive T cells to
apoptosis [36].
Many of these studies have, however, investigated the
mechanisms of AIT in the context of naı¨ve T cells.
Allergen or autoreactive T cells either involved in ongo-
ing or previous disease will be effector or memory T cells.
These previously activated T cells show responses that
are distinct from those of naı¨ve T cells. Critically, they
can be activated by lower levels of antigen and do not
necessarily require costimulatory signals to make an
effector response [37]. These differences suggest that
effector and memory T cells will fail to be tolerised by
AIT, instead potentially causing more immune-driven
damage.
Our recent studies have investigated the consequences of
exposing memory T cells to AIT. In a mouse allergy
model, this response varied depending on the phenotype
of the targeted memory cells with effector memory T cells
undergoing a greater reduction in their subsequent
responses than central memory T cells [38]. This might
have consequences for when best to apply AIT in seasonal
allergies. Effector memory T cells would be expected to
be dominant during active allergen exposure, whereas
immune memory during the ‘off-season’ might be main-
tained predominantly by central memory T cells. A good
knowledge of the target cell population is, therefore,
likely to be key to selecting the most effective treatment
strategy. Similarly, while memory T cells proved to be
initially resistant to AIT, they were altered such that
further activation led to apoptosis [39]. These data
suggest that memory cells retain information about their
activation history which affects their subsequent
responses. Potentially this cellular memory is retained
via epigenetic changes to the cell’s DNA. Indeed, we
recently demonstrated that effector T cells silenced by
AIT must express the cell surface protein, PD-1 [40].
Ligation of this inhibitory receptor serves to diminish
TCR-driven T cell activation/function and its expression
is usually tightly related to TCR ligation. AIT led to DNACurrent Opinion in Pharmacology 2015, 23:11–16
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Mechanisms of action of AIT. AIT can alter the responses of allergen- or self-reactive T cells via a number of mechanisms. In some cases, the
pathologic T cells are deleted following recognition of antigen on tolerising APCs. Alternatively, these T cells can be modulated either
differentiating into regulatory T cells that can suppress the immune response, or altering their effector response by decreasing inflammatory
cytokine production or increasing expression of immunomodulatory molecules such as IL-10 or PD-1.demethylation within the PD-1 gene promoter, enabling
long-term expression of the receptor. These data begin to
provide a molecular basis for the loss of pathogenic T cell
function following AIT.
Future perspectives
From its demonstrated effectiveness in rodent models of
autoimmune and allergic diseases, AIT has reached im-
plementation in clinical trials. Key to translational success
will be rigorous interrogation of molecular mechanisms,
particularly in T effector and T memory cells. The use of
peptide-MHC tetramer staining can identify epitope-
specific T cell in a range of human diseases, most notably
allergies where the inciting antigen is well characterized.
This remains more of a challenge for autoimmune dis-
eases with complex autoaggressive T cell repertoires. A
variety of treatment regimes — routes, doses, delivery
systems and proteins versus peptides — are being trialled.
Reaching a consensus from the likely different outcomes
will be challenging at the molecular level. It is necessary
to specifically focus on those T cells with TCRs recog-
nizing the therapeutic antigen. Low cell yields from
patients will make large scale, unbiased, ‘omics’ analyses
impractical. For this we must rely on more advanced
mouse models that allow retrieval of sufficient material
(tolerant T cells) to identify alterations in key genes/
pathways that then can be interrogated more easily in
human studies. These might provide useful biomarkers
(in concert with tetramer staining) for confirming theCurrent Opinion in Pharmacology 2015, 23:11–16 establishment of tolerance and, importantly, for signs
that it is beginning to wane, prompting renewed immu-
notherapy.
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